- Home
- EPRX vs LCTX Comparison
EPRX vs LCTX Comparison
Compare EPRX & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- LCTX
- Stock Information
- Founded
- EPRX 2011
- LCTX 1990
- Country
- EPRX Canada
- LCTX United States
- Employees
- EPRX N/A
- LCTX N/A
- Industry
- EPRX
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPRX
- LCTX Health Care
- Exchange
- EPRX NYSE
- LCTX Nasdaq
- Market Cap
- EPRX 130.0M
- LCTX 118.8M
- IPO Year
- EPRX N/A
- LCTX N/A
- Fundamental
- Price
- EPRX $3.28
- LCTX $0.41
- Analyst Decision
- EPRX Strong Buy
- LCTX Strong Buy
- Analyst Count
- EPRX 1
- LCTX 5
- Target Price
- EPRX $9.00
- LCTX $4.20
- AVG Volume (30 Days)
- EPRX 11.9K
- LCTX 1.8M
- Earning Date
- EPRX 05-07-2025
- LCTX 03-10-2025
- Dividend Yield
- EPRX N/A
- LCTX N/A
- EPS Growth
- EPRX N/A
- LCTX N/A
- EPS
- EPRX N/A
- LCTX N/A
- Revenue
- EPRX N/A
- LCTX $9,499,000.00
- Revenue This Year
- EPRX N/A
- LCTX $25.10
- Revenue Next Year
- EPRX N/A
- LCTX $35.67
- P/E Ratio
- EPRX N/A
- LCTX N/A
- Revenue Growth
- EPRX N/A
- LCTX 6.19
- 52 Week Low
- EPRX $2.20
- LCTX $0.40
- 52 Week High
- EPRX $4.48
- LCTX $1.56
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- LCTX 26.71
- Support Level
- EPRX N/A
- LCTX $0.47
- Resistance Level
- EPRX N/A
- LCTX $0.55
- Average True Range (ATR)
- EPRX 0.00
- LCTX 0.04
- MACD
- EPRX 0.00
- LCTX -0.00
- Stochastic Oscillator
- EPRX 0.00
- LCTX 8.18
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.